What Is Genmab A/S (GMAB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Genmab A/S's intrinsic value is estimated at a composite $26.16, showing conflicting signals at the current price of $28.73. While the average implied return is -8.9%, model disagreement is elevated with a gap of +163.3% between the most bullish and bearish estimates. The most optimistic model, ML-RIV, places fair value at $50.35 (+75.2%), while Dynamic NAV — the most conservative — estimates $3.43 (-88.1%). This +163.3% gap reflects genuine analytical uncertainty about Genmab A/S's intrinsic worth.
What Do the Models Say About GMAB?
13 of 13 models are currently active for GMAB. Of these, 6 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates GMAB's intrinsic value at $28.89, implying +0.6% upside from the current price. See which stocks rank higher →
How Does GMAB Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, GMAB ranks #65 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a pharmaceutical industry, Genmab A/S operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating GMAB should weigh these sector-specific dynamics alongside our model-derived fair values.
Is GMAB a Value Trap?
The Value Trap algorithm is not active for GMAB. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Genmab A/S. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Genmab A/S's fundamental quality profile registers 6.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +163.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every GMAB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across GMAB's 13 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad